This is an interesting observation because EGFR colocalisation with lipid rafts is correlated with resistance to gefitinib in breast cancer cell lines expressing wtEGFR, and disrupting rafts by depleting plasma membrane cholesterol with lobostatin was found to re-sensitise these resistant cell lines to EGFR-TKIs [215]. Here, EGFR is linked to breast carcinoma.